Silver(I) and rhenium(I) metal complexes of a 2,2′-bipyridine-functionalized third-generation tris(pyrazolyl)methane ligand

2016 ◽  
Vol 72 (11) ◽  
pp. 826-831 ◽  
Author(s):  
Radu F. Semeniuc ◽  
Daniel L. Reger ◽  
Mark D. Smith
Keyword(s):  
Biological Activity ◽  
Coordination Polymer ◽  
Metal Complexes ◽  
Contrast Agents ◽  
Coordination Mode ◽  
Mri Contrast Agents ◽  
Third Generation ◽  
Supramolecular Systems ◽  
Mri Contrast ◽  
One Dimensional

Heterotopic ligands offer the possibility of preparing polynuclear bimetallic complexes. Recent studies of heteroditopic ligands and their metal complexes have focused on novel supramolecular systems, biological activity, and the development of MRI contrast agents. The heteroditopic ligand Bipy–CH2–O–CH2–C(pz)3(Bipy-L; Bipy is 2,2′-bipyridine and pz is pyrazolyl) reacts with AgBF4to produce the coordination polymercatena-poly[[silver(I)-(μ-5-{[tris(pyrazol-1-yl)methoxy]methyl-κ2N,N′}-2,2′-bipyridine-κ2N,N′)] diethyl ether hemisolvate], {[Ag(C22H20N8O)]BF4·0.5C4H10O}n, and with Re(CO)5Br to form the discrete compound bromidotricarbonyl(5-{[tris(pyrazol-1-yl)methoxy]methyl}-2,2′-bipyridine-κ2N,N′)rhenium(I), [ReBr(C22H20N8O)(CO)3]. The silver(I) compound is a one-dimensional coordination polymer, built up by a κ2coordination mode of the bipyridine group and a κ2–κ0coordination mode of the –C(pz)3donor set. In [ReBr(Bipy-L)(CO)3], the ligand coordinates onlyviathe bipyridine end, leaving the –C(pz)3donor set free for further coordination interactions.

Cubosomes as Carriers for MRI Contrast Agents

2017 ◽  
Vol 24 (5) ◽  
pp. 470-482 ◽  
Author(s):  
Nicolas Alcaraz ◽  
Ben J. Boyd
Keyword(s):  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Mri Contrast

Biocompatible dextran-coated gadolinium-doped cerium oxide nanoparticles as MRI contrast agents with high T1 relaxivity and selective cytotoxicity to cancer cells

2021 ◽  
Author(s):  
Anton Popov ◽  
Maxim Artemovich Abakumov ◽  
Irina Savintseva ◽  
Artem Ermakov ◽  
Nelly Popova ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Cerium Oxide Nanoparticles ◽  
Oxide Nanoparticles ◽  
Resonance Imaging ◽  
Mri Contrast ◽  
Selective Cytotoxicity ◽  
Magnetic Resonance Imaging Mri

Gd-based complexes are widely used as magnetic resonance imaging (MRI) contrast agents. The safety of previously approved contrast agents is questionable and is being re-assessed. The main causes of concern...

scholarly journals Correction to: Magnetic Nanoparticles as MRI Contrast Agents

2021 ◽  
Vol 379 (4) ◽  
Author(s):  
Ashish Avasthi ◽  
Carlos Caro ◽  
Esther Pozo-Torres ◽  
Manuel Pernia Leal ◽  
María Luisa García-Martín
Keyword(s):  
Magnetic Nanoparticles ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Mri Contrast

A correction to this paper has been published: https://doi.org/10.1007/s41061-021-00340-y

One-Step Synthesis of Single-Stranded DNA-Bridged Iron Oxide Supraparticles as MRI Contrast Agents

Nano Letters ◽  
2021 ◽  
Vol 21 (7) ◽  
pp. 2793-2799
Author(s):  
Jingfang Zhang ◽  
Zhenghan Di ◽  
Husheng Yan ◽  
Yuliang Zhao ◽  
Lele Li
Keyword(s):  
Iron Oxide ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Single Stranded Dna ◽  
Mri Contrast ◽  
One Step

scholarly journals Study on Establishing Reference Safe Concentrations of MRI Contrast Agents for Optimized Images: Paramagnetic Gd-DTPA-BMEA and Superparamagnetic Ferucarbotran

2021 ◽  
Vol 11 (3) ◽  
pp. 1165
Author(s):  
Wen-Tien Hsiao ◽  
Yi-Hong Chou ◽  
Jhong-Wei Tu ◽  
Ai-Yih Wang ◽  
Lu-Han Lai
Keyword(s):  
Contrast Agent ◽  
Contrast Agents ◽  
Mri Contrast Agents ◽  
Mri Contrast Agent ◽  
In Vitro Experiments ◽  
Mri Contrast ◽  
In Vivo Experiments ◽  
Contrast Agent Injection

The purpose of this study is to establish the minimal injection doses of magnetic resonance imaging (MRI) contrast agents that can achieve optimized images while improving the safety of injectable MRI drugs. Gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA) and ferucarbotran, commonly used in clinical practice, were selected and evaluated with in vitro and in vivo experiments. MRI was acquired using T1-weighted (T1W) and T2-weighted (T2W) sequences, and the results were quantitatively analyzed. For in vitro experiments, results showed that T1W and T2W images were optimal when Gd-DTPA-bisamide (2-oxoethyl) (Gd-DTPA-BMEA) and ferucarbotran were diluted to a volume percentage of 0.6% and 0.05%; all comparisons were significant differences in grayscale statistics using one-way analysis of variance (ANOVA). For in vivo experiments, the contrast agent with optimal concentration percentages determined from in vitro experiments were injected into mice with an injection volume of 100 μL, and the images of brain, heart, liver, and mesentery before and after injection were compared. The statistical results showed that the p values of both T1W and T2W were less than 0.001, which were statistically significant. Under safety considerations for MRI contrast agent injection, optimized MRI images could still be obtained after reducing the injection concentration, which can provide a reference for the safety concentrations of MRI contrast agent injection in the future.

Sign in / Sign up

Export Citation Format

Share Document